Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study
Hossein-Ardeschir Ghofrani,Gérald Simonneau,Andrea M D'Armini,Peter Fedullo,Luke S Howard,Xavier Jaïs,David P Jenkins,Zhi-Cheng Jing,Michael M Madani,Nicolas Martin,Eckhard Mayer,Kelly Papadakis,Dominik Richard,Nick H Kim,MERIT study investigators,Irene Lang,Christian Kähler,Marion Delcroix,Zoheir Bshouty,Pablo Sepulveda Varela,Zhi-Cheng Jing,Yuanhua Yang,Jinming Liu,Gangcheng Zhang,Nuofu Zhang,Yuhong Mi,Xianyang Zhu,Pavel Jansa,Xavier Jaïs,Grégoire Prévot,Hélène Bouvaist,Olivier Sanchez,Friedrich Grimminger,Matthias Held,Heinrike Wilkens,Stephan Rosenkranz,Ekkehard Grünig,Kristóf Karlócai,András Temesvári,Istvan Edes,Sigita Aidietienė,Skaidrius Miliauskas,Tomas Rene Pulido Zamudio,Carlos Jerjes Sanchez,Anton Vonk Noordegraaf,Jerzy Lewczuk,Piotr Podolec,Jarosław Kasprzak,Tatiana Mularek-Kubzdela,Ryszard Grzywna,Keertan Dheda,Olga Moiseeva,Alexander Chernyavskiy,Vladimir Shipulin,Olga Barbarash,Tamila Martynyuk,Hyung-Kwan Kim,Jun-Bean Park,Jae Seung Lee,Rudolf Speich,Silvia Ulrich,John-David Aubert,Arintaya Phrommintikul,Nattapong Jaimchariyatam,Suree Sompradeekul,Zeynep Pinar Onen,Gulfer Okumus,Lyubomyr Solovey,Volodymyr Gavrysyuk,Luke Howard,Joanna Pepke-Zaba,Robin Condliffe,John McConnell,Kim Kerr,Lan Hieu Nguyen,Nguyen Vinh Pham
DOI: https://doi.org/10.1016/s2213-2600(24)00027-4
IF: 102.642
2024-04-01
The Lancet Respiratory Medicine
Abstract:BACKGROUND: Macitentan is beneficial for long-term treatment of pulmonary arterial hypertension. The microvasculopathy of chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension are similar.METHODS: The phase 2, double-blind, randomised, placebo-controlled MERIT-1 trial assessed macitentan in 80 patients with CTEPH adjudicated as inoperable. Patients identified as WHO functional class II-IV with a pulmonary vascular resistance (PVR) of at least 400 dyn·s/cm<sup>5</sup> and a walk distance of 150-450 m in 6 min were randomly assigned (1:1), via an interactive voice/web response system, to receive oral macitentan (10 mg once a day) or placebo. Treatment with phosphodiesterase type-5 inhibitors and oral or inhaled prostanoids was permitted for WHO functional class III/IV patients. The primary endpoint was resting PVR at week 16, expressed as percentage of PVR measured at baseline. Analyses were done in all patients who were randomly assigned to treatment; safety analyses were done in all patients who received at least one dose of the study drug. This study is registered with ClinicalTrials.gov, number NCT02021292.FINDINGS: Between April 3, 2014, and March 17, 2016, we screened 186 patients for eligibility at 48 hospitals across 20 countries. Of these, 80 patients in 36 hospitals were randomly assigned to treatment (40 patients to macitentan, 40 patients to placebo). At week 16, geometric mean PVR decreased to 71·5% of baseline in the macitentan group and to 87·6% in the placebo group (geometric means ratio 0·81, 95% CI 0·70-0·95, p=0·0098). The most common adverse events in the macitentan group were peripheral oedema (9 [23%] of 40 patients) and decreased haemoglobin (6 [15%]).INTERPRETATION: In MERIT-1, macitentan significantly improved PVR in patients with inoperable CTEPH and was well tolerated.FUNDING: Actelion Pharmaceuticals Ltd.
respiratory system,critical care medicine